John H. Strickler

机构：Duke University, Cancer Institute (WIA), Duke Medical Center, Durham VA Medical Center, Duke University Hospital, Duke Cancer Institute · ORCID：0000-0001-7579-1175

发表论文 433 篇 · 总被引 9842 次 · h-index 39

代表论文

• Tucatinib plus trastuzumab for chemotherapy-refractory, HER2 + , RAS wild-type metastatic colorectal cancer (MOUNTAINEER): final analysis (2026 · Nature Communications · 被引 12)
• A Phase III study of perioperative dostarlimab in patients with dMMR/MSI-H resectable colon cancer: AZUR-2 study design (2026 · Future Oncology · 被引 9)
• Zolbetuximab + pembrolizumab and chemotherapy as first-line treatment for patients with CLDN18.2-positive, HER2-negative, PD-L1-positive locally advanced unresectable or metastatic G/GEJ adenocarcinoma: Phase 3, double-blind, randomized trial (LUCERNA). (2026 · Journal of Clinical Oncology · 被引 7)
• Abstract CT021: Preliminary safety and clinical activity of zoldonrasib (RMC-9805), an oral, RAS(ON) G12D-selective, tri-complex inhibitor in patients with previously treated KRAS G12D non-small cell lung cancer (NSCLC) (2026 · Cancer Research · 被引 4)
• Framework for cancer evolution profiling and interception in colorectal cancer: ASCEND-CRC program (2026 · Cancer Cell · 被引 3)
• Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid Tumors (2026 · Journal of Clinical Oncology · 被引 2)